OBJECTIVES: To compare the clinical efficacy of brodalumab, an anti-IL 17RA human monoclonal antibody, with approved biologic therapies and apremilast for the treatment of moderate-to-severe psoriasis. METHODS: A PRISMA-compliant systematic literature review identified RCTs reporting induction phase Psoriasis Area Severity Index (PASI) responses for therapies at European Medicines Agency approved doses. The primary analysis examined the proportion of patients achieving PASI 50, 75, 90 or 100 responses using a random effects Bayesian multinomial likelihood model with probit link, without and with an adjustment for study-level placebo responses. A second analysis assessed the number of patients with Physician Global Assessment (PGA) scores of 0 or 1. Effects of alternative inclusion criteria, such as including unlicensed therapies and introducing restrictions based on disease severity, were explored in a series of sensitivity analyses. The NMA adhered to NICE Decision Support Unit recommended methods. RESULTS: A total of 41 studies reporting PASI outcomes were included in the base case NMA. All active therapies were found to be significantly more efficacious than placebo at achieving all levels of PASI response. Based on PASI 100 response (complete clearance), the most efficacious therapies in the network were brodalumab and ixekizumab, followed by infliximab and secukinumab. Brodalumab was significantly more efficacious than adalimumab, apremilast, etanercept and ustekinumab. This ranking was consistent for PASI 50, 75 and 90 outcomes, as well as the PGA response analysis and all sensitivity analyses. CONCLUSIONS: Results of the NMA reflect the results from recent pivotal trials which found that high levels of complete clearance can be achieved with brodalumab. Based on currently available evidence, the induction-phase efficacy of brodalumab is similar to ixekizumab, secukinumab and infliximab and superior to other approved therapies, including adalimumab, apremilast, etanercept, and ustekinumab. Analysis of longer-term data is needed to understand the comparative efficacy biological therapies beyond induction.